• Archives of Plastic Surgery
• /
• 제39권2호
• /
• pp.150-153
• /
• 2012

Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing. In particular, guidelines for flap operations in hemophilia B patients have still not been defined, and case reports are rare. We reconstructed the heel of a 41-year-old male hemophilia B patient using a reverse sural artery flap operation. The patient presented with mild hemophilia, having 27% of the normal value of coagulation factor IX. Coagulation and the changing value of the coagulation factor were regularly measured, and 70% of the normal value of coagulation factor IX was maintained through the injection of recombinant coagulation factors and antihemorrhagics. Hematoma developed twice (postoperative day [POD] 5 and POD 7) and in each case the hematoma was removed. Injections of recombinant coagulation factors and antihemorrhagics were continuously administered until postoperative week 2. When the coagulation factors were within normal ranges. In this article, a hemophilia B patient underwent reverse sural artery flap surgery and the healing progress was analyzed. We conclude that higher than baseline levels of coagulation factors are needed for successful healing in reverse sural artery flap surgery.

• 대한약침학회지
• /
• 제18권4호
• /
• pp.7-11
• /
• 2015

Objectives: Bee venom (BV) is a complex mixture of proteins and contains proteins such as phospholipase and melittin, which have an effect on blood clotting and blood clots. The mechanism of action of honey bee venom (HBV, Apis mellifera) on human plasma proteins and its anti-thrombotic effect were studied. The purpose of this study was to investigate the anti-coagulation effect of BV and its effects on blood coagulation and purification. Methods: Crude venom obtained from Apis mellifera was selected. The anti-coagulation factor of the crude venom from this species was purified by using gel filtration chromatography (sephadex G-50), and the molecular weights of the anti-coagulants in this venom estimated by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Blood samples were obtained from 10 rabbits, and the prothrombin time (PT) and the partial thromboplastin time (PTT) tests were conducted. The approximate lethal dose (LD) values of BV were determined. Results: Crude BV increased the blood clotting time. For BV concentrations from 1 to 4 mg/mL, clotting was not observed even at more than 300 seconds, standard deviations $(SDs)={\pm}0.71$; however, clotting was observed in the control group 13.8 s, $SDs={\pm}0.52$. Thus, BV can be considered as containing anti-coagulation factors. Crude BV is composed 4 protein bands with molecular weights of 3, 15, 20 and 41 kilodalton (kDa), respectively. The $LD_{50}$ of the crude BV was found to be $177.8{\mu}g/mouse$. Conclusion: BV contains anti-coagulation factors. The fraction extracted from the Iranian bees contains proteins that are similar to anti-coagulation proteins, such as phospholipase $A_2(PLA_2)$ and melittin, and that can increase the blood clotting times in vitro.

• 혜화의학회지
• /
• 제9권2호
• /
• pp.241-250
• /
• 2001

A study on relation of angiogenesis and blood stagnation in cancer was done, and the results were as follows. 1. Angiogenesis is a sequence of vascular proliferation and accomplished by regulation of anti-angiogenesis factor and indicating factor. These factors are secreted in the course of blood coagulation, inflammation, and regeneration. 2. Angiogenesis in cancer is a important action in growth of tumor and metastasis because it supply oxygen and nutrition. 3. The complicated processes, for example, platelet coagulation, action of coagulator factor & dissolution factor and interaction of variety factors are related to blood stasis and promoting blood circulation to remove blood stasis in oriental medicine. 4. Promoting blood circulation to remove blood stasis is expected to suppress angiogenesis, and we expect advanced study will be accomplished in future.

• Journal of Ginseng Research
• /
• 제41권2호
• /
• pp.120-126
• /
• 2017

Background: The present study investigated the effect of ginseng berry hot water extract (GBx) on blood flow via the regulation of lipid metabolites and blood coagulation in rats fed a high-fat diet (HFD). Methods: Sixty rats were divided into five groups in descending order of body weight. Except for the control group, the other four groups were fed a HFD containing 45% kcal from fat for 11 wk without GBx. GBx groups were then additionally treated by gastric gavage with GBx dissolved in distilled water at 50 (GBx 50) mg/kg, 100 (GBx 100) mg/kg, or 150 (GBx 150) mg/kg body weight for 6 wk along with the HFD. To investigate the effects of GBx on rats fed a HFD, biochemical metabolite, blood coagulation assay, and histological analysis were performed. Results: In the experiments to measure the serum levels of leptin and apolipoprotein B/A, GBx treatment attenuated the HFD-induced increases in these metabolites (p < 0.05). Adiponectin and apolipoprotein E levels in GBx-treated groups were significantly higher than the HFD group. Prothrombin time and activated partial thromboplastin time were increased in all GBx-treated groups. In the GBx-treated groups, the serum levels of thromboxane $A_2$ and serotonin were decreased and concentrations of serum fibrinogen degradation products were increased (p < 0.05). Moreover, histomorphometric dyslipidemia-related atherosclerotic changes were significantly improved by treatment with GBx. Conclusion: These results suggest the possibility that GBx can ameliorate blood flow by decreasing intima-media thickness via the regulation of blood coagulation factors related to lipid metabolites in rats fed a HFD.

• Current Optics and Photonics
• /
• 제2권6호
• /
• pp.623-628
• /
• 2018

Clotting properties of human blood are important clinical information to monitor for patients with platelet and coagulation disorders. Most devices used to diagnose these disorders utilize blood plasma together with tissue factors and $Ca^{{+}{+}}$ additives. In some instruments, magnetic particles were mixed with blood samples and a rotating magnetic field was applied, resulting in the rotation of magnetic particles, which was probed by impinging light. The working principle seems obvious yet had not been investigated in depth. We modeled the collective behavior of light propagating through magnetic needles, aligned in the direction of the rotating external magnetic field, with scattering light analysis software. Simulation results indicated that the scattering pattern undergoes periodic undulations with respect to the slant angle of the magnetic needles. Also provided is a means of extracting meaningful information from the scattering measurement.

• Journal of Ginseng Research
• /
• 제22권3호
• /
• pp.173-180
• /
• 1998

Thrombogenesis and atherosclerosis are mainly caused by platelet aggregation, blood coagulation, and hyperlipidemia. Platelet aggrelation, activated platelet thromboplastin time (APTT) were measured as indexes of blood coagulation and lipid contents in the subjects who have taken red ginseng products (e.g. water extract, tea, drink etc.) for 4 to 5 years. The platelet aggregation in the red ginseng-taking group was significantly decreased, as compared with the non-red ginseng-intaking group, when platelets were stimulated by 100 $\mu\textrm{g}$/ml of collagen (P<0.01). The atherogenic index and the ratio of triglyceride to HDL-cholesterol in blood, the risk factors of atherosclerosis, were decreased in the subjects of ginseng group, compared with that in control group. APTT was also prolonged to greater extent in ginseng group than in control group. These results suggest that long-term intake of ginseng products may help to prevent the risks of thrombogenesis and atherosclerosis.

• 동의생리병리학회지
• /
• 제37권6호
• /
• pp.165-171
• /
• 2023

COVID-19 infection heightens the risk of thromboembolism. To see the similarities between the COVID-19 infection and Taeyang blood retention pattern, we conducted a PubMed search using specific terms related to blood circulation issues in the context of COVID-19, summarizing findings from 13 cases and 4 observational studies involving actual patients. Patients with COVID-19 are at risk of blood coagulation due to factors such as viral-induced cytokine storms, vascular endothelial dysfunction, reduced mobility in bedridden or isolated individuals, and resulting constipation. Additionally, cytokine storms and severe inflammation can lead to delirium in COVID-19 patients. The Taeyang blood retention pattern manifests as symptoms arising from delirium and an increased blood coagulation tendency in patients with a robust immune response. According to the Sanghan theory, certain herbal treatments can alleviate symptoms in patients with a tight lower abdomen who do not experience urinary issues. Studies show that components like Persicae Semen and Rhei Redix et Rhizoma in these prescriptions enhance blood circulation and reduce hypercoagulability. Additionally, these treatments aim to promote blood flow by relieving abdominal pressure through facilitating bowel movements. The excessive inflammation and heightened blood coagulation tendency in COVID-19 resemble the Taeyang blood retention pattern, although they are caused by different pathogens. Reinterpreting classical oriental medicine's principles in a modern context may enhance our understanding of traditional East Asian Medicine and foster future developments.

• 한국식품영양과학회지
• /
• 제44권8호
• /
• pp.1105-1113
• /
• 2015

혈행 개선 기능성을 평가하기 위하여 8주 동안 일반식이와 고지방식이를 제공하는 그룹에 오메가-3 지방산과 복분자종자유를 일정량 제공하는 실험을 실시하였다. 실험군은 일반식이 그룹과 고지방식이 그룹으로 나누어 각 그룹 내에 음성대조군, 양성대조군(오메가-3 지방산), 복분자종자유(2 g, 4 g/2,000 kcal) 급이군으로 구성하였다. 양성대조군과 복분자종자유는 매일 경구 투여되었고 실험기간 종료 후 동물을 희생시켜 혈액과 장기를 얻어 혈중중성지방 및 콜레스테롤, 혈행 개선에 관련된 바이오마커(coagulation factor7, 12, serotonin과 TXB2)를 측정하였는데, 그 결과 복분자종자유는 혈중지질의 농도 개선을 통해 혈액의 점도를 감소시키고 혈액의 응고를 억제하여 혈행을 개선하는 기능성이 있는 것을 확인하게 되었다. 따라서 복분자종자유를 이용한 건강기능식품 개발은 혈관질환 환자들에게 혈행 개선을 통한 건강증진 효과를 보여줄 것으로 판단된다.

• 대한한방부인과학회지
• /
• 제19권1호
• /
• pp.139-154
• /
• 2006

Objective : This experimental study was carried out to investigate anti-coagulation effects and mechanism of Hongdeung-tang on the dissentimenated intravascular coagulation Methods : Each 10 rats were classified as normal gorup, control group and treated group. The control group was given a 0.5mg/ml endotoxin intra-vein injection and was occurred Disseminated Intravascular Coagulation(DIC). The treated group were orally administrated 1ml Hongdeung-tang concentration once a day for 6 days and then it was treated the same as the control group. We took the blood from heart and were investigated number of Platelet and white blood cell(WBC), fibrinogen concentration, prothrombin time(PT), activated partial thromboplastin time(APTT), interleukin-6(IL-6), Tumor Necrosis $Factor-{\alpha}(TNF-{\alpha})$, Prostaglandin $E2(PGE_2)$ from them. Results : There were a statistically significant increase of platelet and fibrinogen concentration in the treated group compared to the treated group. The PT was a significantly reduced in treated group compared to the control group. There was no significant change in numbers of WBC and APTT between control and treated group. On the contrary, the number of PT, IL-6, $TNF-{\alpha}$, $PGE_2$ were significantly decreased in treated group compared to the control group. Conclusion : DIC which was occurred by endotoxin intravenous injection seems to related to the increase of IL-6, $TNF-{\alpha}$, $PGE_2$ and Hongdeung-tang has an effect that supress those factors. we can assume Hongdeung-tang has an anti-coagulation effect by those supressing effect.

• Animal cells and systems
• /
• 제7권3호
• /
• pp.255-259
• /
• 2003

Mutations in the factor Ⅴ gene are major risk markers for venous thrombosis. Several factors for blood coagulation have been related with cardiovascular disease. Ⅰ investigated genotype distribution for three mutations (G1691 A, A2379G and G2391 A) of the factor Ⅴ gene in the Korean population. Genotype frequencies were examined by polymerase chain reaction in 135 patients with coronary artery disease (CAD) and 116 healthy subjects. For the G1691A mutation (factor Ⅴ